Applicant, as named in the Orange Book

Teva Pharms Intl

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis

None.

24 Oct 2026Synribo · Enters 12-month window basis: patent, carve-out possible26 Oct 2026

Products without listed protection (1)

Drug	Ingredient	NDA	Earliest generic entry	Basis
Amrix · 2 strengths cyclobenzaprine hydrochloride	cyclobenzaprine hydrochloride	021777	open now	no listed protection